New
HealthMore in Health→
Teclistamab vs Lenalidomide-Dexamethasone Tested in High-Risk Smoldering Myeloma
Key Takeaways
- Nature Medicine published a randomized phase 2 trial on 11 September 2026 comparing teclistamab with lenalidomide-dexamethasone in high-risk smoldering multiple myeloma.
- The study is known as ImmunoPRISM and focuses on the precursor stage of multiple myeloma.
- Teclistamab is a BCMA-directed bispecific antibody; lenalidomide plus dexamethasone is an established all-oral combination.
- The journal summary reports a higher result for patients on the trial's highlighted measure, with full data in the paper.
DE
DT Editorial Team··via nature.com